XOMA - Xoma Corporation

-

$undefined

N/A

(N/A)

Xoma Corporation NasdaqGM:XOMA XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Location: 2200 Powell Street, Emeryville, CA, 94608, United States | Website: https://www.xoma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

327M

Cash

92.65M

Avg Qtr Burn

-1.651M

Short % of Float

1.91%

Insider Ownership

0.94%

Institutional Own.

62.68%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Initiation

Vudalimab (PD-1 x CTLA-4) Details
Non-small cell lung carcinoma

Phase 2

Update

Vudalimab (PD-1 x CTLA-4) Details
Castration-resistant prostate cancer

Phase 2

Update

XmAb564 (IL2-Fc) Details
Atopic dermatitis, Psoriasis

Phase 1b

Update

XmAb541 Details
Cancer, Ovarian cancer

Phase 1

Data readout

XmAb662 (IL12-Fc) Details
Solid tumor/s, Cancer

Phase 1

Update

Failed

Discontinued